1,411 Shares in IDEXX Laboratories, Inc. $IDXX Bought by True North Advisors LLC

True North Advisors LLC purchased a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 1,411 shares of the company’s stock, valued at approximately $793,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in IDXX. Empowered Funds LLC grew its position in shares of IDEXX Laboratories by 6.6% during the 1st quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock valued at $646,000 after acquiring an additional 95 shares during the period. Sivia Capital Partners LLC acquired a new position in IDEXX Laboratories in the 2nd quarter worth about $265,000. Jump Financial LLC raised its holdings in IDEXX Laboratories by 1,006.4% in the 2nd quarter. Jump Financial LLC now owns 5,532 shares of the company’s stock worth $2,967,000 after purchasing an additional 5,032 shares during the period. Cary Street Partners Financial LLC purchased a new position in IDEXX Laboratories during the second quarter worth approximately $164,000. Finally, Sei Investments Co. boosted its position in IDEXX Laboratories by 218.7% during the second quarter. Sei Investments Co. now owns 120,587 shares of the company’s stock worth $64,678,000 after purchasing an additional 82,755 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Trading Down 1.5%

Shares of IDEXX Laboratories stock opened at $567.44 on Friday. The firm has a market capitalization of $44.76 billion, a PE ratio of 41.78, a P/E/G ratio of 3.10 and a beta of 1.55. IDEXX Laboratories, Inc. has a twelve month low of $513.02 and a twelve month high of $769.98. The firm’s 50-day moving average price is $554.49 and its 200 day moving average price is $599.94. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, topping the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.12 billion. During the same period in the previous year, the business earned $2.91 EPS. IDEXX Laboratories’s quarterly revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, sell-side analysts predict that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

Analysts Set New Price Targets

IDXX has been the topic of several research analyst reports. Citigroup initiated coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price objective on the stock. UBS Group reduced their target price on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research note on Tuesday, April 28th. Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Weiss Ratings cut shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Tuesday. Finally, Stifel Nicolaus cut their price target on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a report on Tuesday, March 31st. Six analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $751.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.